PCSK9 and acute coronary syndrome: A study has shown that intensive TG reduction along with TC and LDL-C lowering with PCSK9 inhibitor gradually provide additional deferred improvement in coronary flow in IRA 6 months after coronary angioplasty for acute coronary syndrome [34].